Revisiting Early Psychedelic Therapy Trials: US & Canada, 1965–1977

Early Controlled Trials Found No Lasting Benefits from Psychedelic Therapy

A recent review published on September 7, 2026, in OpenAlex (source) challenges the prevailing narrative that early psychedelic therapy trials were methodologically inadequate. The authors systematically examined 11 controlled studies conducted in the United States and Canada between 1965 and 1977, focusing on psychedelic-assisted therapy for alcohol and opioid use disorders as well as psychoneuroses. Contrary to common belief, these studies largely adhered to the regulatory and evidentiary standards of their era, including the use of control groups and efforts to maintain blinding.

The review’s central finding is that most of these early trials did not demonstrate durable improvements in patient outcomes beyond a few weeks after treatment. While some studies reported short-term benefits—often described as a "positive afterglow"—these effects typically dissipated within a month. This stands in contrast to the narrative that methodological flaws, rather than lack of efficacy, explain the limited impact of early psychedelic research.

Mechanisms, Patient Selection, and the Role of Mystical Experience

The review highlights that early researchers attempted to address many of the same methodological challenges that persist in contemporary psychedelic trials, such as maintaining effective blinding and establishing credible active control conditions. Despite these efforts, the lack of sustained benefit suggests that factors beyond study design may limit the long-term efficacy of psychedelic therapy.

One key insight is the need to reconsider patient selection. The reviewed studies primarily targeted individuals with chronic conditions, such as long-standing substance use disorders and psychoneuroses. The authors suggest that psychedelic therapy may hold more promise for non-chronic or acute conditions, where the "afterglow" period could be leveraged as a therapeutic window for behavioral interventions.

Another important point is the critique of the current focus on mystical or peak experiences as the primary mechanism of action. The review notes that early trials did not consistently link such experiences to lasting improvements, raising questions about the generalizability of this mechanism across patient populations and diagnoses.

Implications for Modern Clinical Trials and Regulatory Scrutiny

These findings have significant implications for the design and interpretation of modern psychedelic clinical trials. Regulators such as the U.S. Food and Drug Administration (FDA) and Health Canada may look more critically at claims of durable efficacy, especially for chronic conditions. The review underscores the importance of robust control conditions, extended follow-up periods, and clear criteria for clinically meaningful change.

For researchers, the review suggests that trial designs should incorporate stronger psychotherapeutic frameworks to support sustained behavioral change, rather than relying solely on the pharmacological or experiential effects of psychedelics. This may require integrating evidence-based psychotherapy modalities and carefully timing interventions to coincide with periods of heightened psychological receptivity.

Notably, the review points out that the "afterglow"—a period of increased openness and well-being following psychedelic administration—may represent a fleeting but valuable opportunity for therapeutic engagement. Future studies could focus on optimizing interventions during this window, rather than expecting the drug experience alone to produce lasting change.

Risks, Unknowns, and the Need for Cautious Optimism

The lack of durable effects observed in early trials raises important questions about the long-term safety and efficacy of psychedelic therapy. While modern studies often report promising short-term outcomes, the durability of these effects remains uncertain, particularly in the absence of ongoing psychotherapeutic support.

There is also a risk that overemphasis on mystical experiences or rapid symptom relief could lead to unrealistic expectations among patients, clinicians, and policymakers. The review cautions that without rigorous, long-term follow-up and transparent reporting of outcomes, the field may repeat past cycles of enthusiasm followed by disillusionment.

One non-obvious implication is that regulatory agencies may begin to require more stringent post-approval monitoring and real-world evidence collection for psychedelic therapies, especially if initial trials do not demonstrate sustained benefits. This could shape the pace and nature of future approvals and reimbursement decisions.

Looking Forward: Rethinking Efficacy and Trial Design in Psychedelic Science

The re-evaluation of early psychedelic therapy trials invites a more nuanced understanding of both historical and contemporary research. By acknowledging the methodological rigor of past studies and their limitations in demonstrating durable effects, the field can better design trials that address the complex interplay of drug, patient, and context.

As the psychedelic research community moves forward, there is a clear need for trials that prioritize patient selection, integrate strong psychotherapeutic frameworks, and focus on mechanisms beyond the acute drug experience. Only through such careful, evidence-driven approaches can the field hope to deliver on the promise of psychedelic-assisted therapy while avoiding the pitfalls of past decades.

How we research: This article was written by Dr. Alex Morgan, PhD (Neuroscience), reviewed by Dr. Emily Tran, MD, on 2026-09-08. Primary sources include the OpenAlex review and original FDA and Health Canada trial documentation.